RefleXion Medical

RefleXion Medical is a biotargeting oncology company based in Hayward, California, founded in 2009 by Sam Mazin, Ph.D., and Akshay Nanduri.

The company focuses on revolutionizing cancer treatment through its innovative biology-guided radiotherapy (BgRT) system, which utilizes the biology of tumors to direct radiation precisely. This approach allows for effective treatment of both primary and metastatic tumors while minimizing damage to healthy tissue. The flagship product line includes the RefleXion X system, which features the first-generation RefleXion X1 platform, cleared by the FDA in February 2023, and the next-generation RefleXion X2, set for FDA clearance in January 2026. The system employs Positron Emission Tomography (PET) imaging to turn cancer cells into real-time biological beacons, guiding external-beam radiotherapy. RefleXion serves oncology centers, hospitals, and cancer clinics, primarily in the United States, and collaborates with major cancer centers and pharmaceutical companies to enhance cancer care.